HPLC assay for determination of amphotericin B in biological samples

Biomedical Chromatography

Volumn 22, Issue 4, 2008, Pages 402-407

  Espada, R ^a   Josa, J M ^b   Valdespina, S ^a   Dea, M A ^a   Ballesteros, M P ^a   Alunda, J M ^c   Torrado, J J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Lavetpa Veterinary Clinic   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Amphotericin B; High pressure liquid chromatography; Pharmacokinetics; Validation

Indexed keywords

EFFLUENTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY;

ACETIC ACID/WATER; AMPHOTERICIN B; BIOLOGICAL SAMPLES; CHROMATOGRAPHIC SEPARATIONS; CONCENTRATION RANGES; HPLC METHOD; LINEAR RESPONSE; MOBILE PHASIS; REVERSE PHASIS; VALIDATION;

PHARMACOKINETICS;

ACETIC ACID; ACETONITRILE; AMPHOTERICIN B; WATER;

ANIMAL TISSUE; ARTICLE; BONE MARROW; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; EFFLUENT; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY; LIVER; MONITORING; MOUSE; NONHUMAN; SEPARATION TECHNIQUE; SINGLE DRUG DOSE; SPLEEN; VALIDATION PROCESS;

CANIS FAMILIARIS; MUS;

EID: 42549092221     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.947     Document Type: Article

References (20)

1. Alak A, Moy S and Bekersky I. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Therapeutic Drug Monitoring 1996; 18: 604-609.
2. Andes D, Safdar N, Marchillo K and Conklin R. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrobial Agents and Chemotherapy 2006; 50: 674-684.
3. Barrat G and Legrand P. Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. Current Opinion in Infectious Diseases 2005; 18: 527-530.
4. Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG, Hawkey PM, Herbrecht R, Marks DI, Moraleda JM, Park GR, Senn SJ and Viscoli C. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clinical Therapeutics 2003; 25: 1295-1320.
5. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN and Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrobial Agents and Chemotherapy 2002; 46: 834-840.
6. Echevarría I, Barturen C, Renedo MJ and Dios-Viéitez MC. High-performance liquid chromatographic determination of amphotericin B in plasma and tissue. Application to pharmacokinetic and tissue distribution studies in rats. Journal of Chromatography A 1998; 819: 171-176.
7. Egger P, Bellmann R and Wiedermann CJ. Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography. Journal of Chromatography B, Biomedical Sciences and Applications 2001; 760: 307-313.
8. Eldem T and Arican-Cellat N. Determination of amphotencin B in human plasma using solid-phase extraction and high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 2001; 25: 53-64.
9. Gallis HA, Drew RH and Pickard WW. Amphotericin B: 30 years of clinical experience. Reviews of Infectious Diseases 1990; 12: 308-329.
10. Hosotsubo H and Hosotsubo K. Improved high-performance liquid chromatographic determination of amphotericin B in human serum and plasma. Journal of Pharmaceutical and Biomedical Analysis 1989; 7: 975-979.
11. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Methodology, ICH Topic Q2B. The European Agency for the Evaluation of Medicinal Products: London, 1996.
12. Lamothe J. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis. The Journal of Small Animal Practice 2001; 42: 170-175.
13. Lue LP, Hadman ST and Vancura A. Liquid chromatographic determination of amphotericin B in different pharmaceuticals. Journal of AOAC International 2002; 85: 15-19.
14. Murray HW. Treatment of visceral leishmaniasis in 2004. The American Journal of Tropical Medicine and Hygiene 2004; 71: 787-794.
15. Noli C and Auxilia ST. Treatment of canine Old World visceral leishmaniasis: a systematic review. Veterinary Dermatology 2005; 16: 213-232.
16. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA and Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. The Lancet Infectious Diseases 2005; 5: 763-774.
17. Olson JA, Adler-Moore JP, Schwartz J, Jensen GM and Proffitt RT. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrobial Agents and Chemotherapy 2006; 50: 2122-2131.
18. Sánchez-Brunete JA, Dea MA, Rama S, Bolás F, Alunda JM, Raposo R, Méndez MT, Torrado-Santiago S and Torrado JJ. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrobial Agents and Chemotherapy 2004; 48: 3246-3252.
19. The United States Pharmacopeia. Rockville, MD, 2006.
20. Tiphine M, Letscher-Bru V and Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transplant Infectious Disease 1999; 4: 273-283.